secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078077
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives
--------------------------------------------------------------------------------

- Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.
- R&D expenses $10.5M (down from $17.9M); G&A $1.8M (down from $3.4M); restructuring charge $4.5M.
- Board initiated review of strategic alternatives; engaged Raymond James as financial advisor.
- Workforce reduced ~75% to preserve capital; majority of severance costs in Q3/Q4 2025.
- Updated Phase 2 DeFianCe data showed statistically significant benefit on ORR and PFS in certain CRC subgroups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/0001104659-25-078077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/tm2523408d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer